Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6237-6245

  Hsu, Wen Ming ^a   Lee, Hsinyu ^b   Juan, Hsueh Fen ^b   Shih, Yu Yin ^b,c   Wang, Bo Jeng ^c   Pan, Chien Yuan ^b   Jeng, Yung Ming ^a   Chang, Hsiu Hao ^a   Lu, Meng Yao ^a   Lin, Kai Hsin ^a   Lai, Hong Shiee ^a   Chen, Wei Jao ^a   Tsay, Yeou Guang ^c   Liao, Yung Feng ^b,c   Hsieh, Fon Jou ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; GLUCOSE REGULATED PROTEIN; GLUCOSE REGULATED PROTEIN 75; TUMOR MARKER; UNCLASSIFIED DRUG; GLUCOSE REGULATED PROTEINS; GLUCOSE-REGULATED PROTEINS; HEAT SHOCK PROTEIN 70; MEMBRANE PROTEIN; PROTEOME;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; CHILD; FEMALE; GENE EXPRESSION REGULATION; INFANT; MALE; METABOLISM; METHODOLOGY; NEWBORN; PRESCHOOL CHILD; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEMBRANE PROTEINS; NEUROBLASTOMA; PROGNOSIS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149157945     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4181     Document Type: Article

References (34)

1. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995;75:2186-95.
2. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
4. Woods WG, Lemieux B, Tuchman M. Neuroblastoma represents distinct clinical-biologic entities: a review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics 1992;89:114-8.
5. Hsu WM, Jen YM, Lee H, et al. The influence of biologic factors on the surgical decision in advanced neuroblastoma. Ann Surg Oncol 2006;13:238-44.
6. Tonini GP. Neuroblastoma: the result of multistep transformation? Stem Cells 1993;11:276-82.
7. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2451-61.
8. Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest 1996;75:659-75.
9. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54.
10. Kitanaka C, Kato K, Ijiri R, et al. Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. J Natl Cancer Inst 2002;94:358-68.
11. Hsu WM, Hsieh FJ, Jeng YM, et al. GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastic tumors. Int J Cancer 2005;113:920-7.
12. Hsu WM, Hsieh FJ, Jeng YM, et al. Calreticulin expression in neuroblastoma-a novel independent prognostic factor. Ann Oncol 2005;16:314-21.
13. Srinivas PR, Verma M, Zhao Y, Srivastava S. Proteomics for cancer biomarker discovery. Clin Chem 2002; 48:1160-9.
14. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol 2005;1:37-50.
15. Wadhwa R, Kaul SC, Ikawa Y, Sugimoto Y. Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype. J Biol Chem 1993;268:6615-21.
16. Kaul SC, Taira K, Pereira-Smith OM, Wadhwa R. Mortalin: present and prospective. Exp Gerontol 2002;37:1157-64.
17. Wadhwa R, Taira K, Kaul SC. Mortalin: a potential candidate for biotechnology and biomedicine. Histol Histopathol 2002;17:1173-7.
18. Liao YF, Wang BJ, Hsu WM, et al. Unnatural amino acid-substituted (hydroxyethyl) urea peptidomimetics inhibit γ-secretase and promote the neuronal differentiation of neuroblastoma cells. Mol Pharmacol 2007;71:588-601.
19. Encinas M, Iglesias M, Liu Y, et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 2000;75:991-1003.
20. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-63.
21. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72.
22. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
23. Tajiri T, Shono K, Fujii Y, et al. Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence in situ hybridization. J Pediatr Surg1999; 34:1615-9.
24. Kopf I, Hanson C, Delle U, Verbiene I, Weimarck A. A rapid and simplified technique for analysis of archival formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization (FISH). Anticancer Res 1996;16:2533-6.
25. Castleberry RP. Neuroblastoma. Eur J Cancer 1997; 33:1430-7; discussion 7-8.
26. Tanaka T, Slamon DJ, Shimoda H, et al. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res 1988;48:1030-4.
27. Yan JX, Devenish AT, Wait R, Stone T, Lewis S, Fowler S. Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of Escherichia coli. Proteomics 2002;2:1682-98.
28. Wadhwa R, Takano S, Kaur K, et al. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 2006;118:2973-80.
29. Wadhwa R, Pereira-Smith OM, Reddel RR, Sugimoto Y, Mitsui Y, Kaul SC. Correlation between complementation group for immortality and the cellular distribution of mortalin. Exp Cell Res 1995;216:101-6.
30. Kaul SC, Matsui M, Takano S, Sugihara T, Mitsui Y, Wadhwa R. Expression analysis of mortalin, a unique member of the Hsp70 family of proteins, in rat tissues. Exp Cell Res 1997;232:56-63.
31. Srokowski T, Pfeifer JD, Li J, Olson LM, Rader JS. Expression and localization of GRP75 in human epithelial tumors and normal tissues. Appl Immunohistochem Mol Morphol 2004;12:132-8.
32. Kuwabara H, Yoneda M, Hayasaki H, Nakamura T, Mori H. Glucose regulated proteins 78 and 75 bind to the receptor for hyaluronan mediated motility in interphase microtubules. Biochem Biophys Res Commun 2006;339:971-6.
33. Nagy JI, Hacking J, Frankenstein UN, Turley EA. Requirement of the hyaluronan receptor RHAMM in neurite extension and motility as demonstrated in primary neurons and neuronal cell lines. J Neurosci 1995;15:241-52.
34. Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res 2005;65:850-60.